XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
1.350
-0.070 (-4.93%)
Nov 4, 2024, 4:00 PM EST - Market closed
XORTX Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 5 | 4 | 12 | 26 | 9 | 8 | |
Market Cap Growth | -54.39% | -63.14% | -53.60% | 177.78% | 19.02% | 29.48% | |
Enterprise Value | 2 | -1 | 3 | 22 | 9 | 8 | |
Last Close Price | 1.35 | 2.31 | 7.27 | 18.45 | 12.26 | 13.81 | |
PE Ratio | - | -2.12 | -1.39 | -12.78 | -7.06 | -13.06 | |
PB Ratio | 2.02 | 0.95 | 1.70 | 1.94 | 7.35 | -36.66 | |
P/FCF Ratio | -1.24 | -0.67 | -1.33 | -5.34 | -12.68 | -31.10 | |
P/OCF Ratio | -1.24 | -0.67 | -1.33 | -5.34 | -12.68 | -31.10 | |
EV/EBITDA Ratio | -0.51 | 0.16 | -0.33 | -9.46 | -8.40 | -16.46 | |
EV/EBIT Ratio | -0.50 | 0.16 | -0.33 | -9.40 | -8.24 | -15.79 | |
EV/FCF Ratio | -0.38 | 0.12 | -0.34 | -4.52 | -12.48 | -30.91 | |
Debt / Equity Ratio | 0.03 | 0.00 | 0.01 | - | - | -0.24 | |
Debt / FCF Ratio | -0.02 | 0.00 | -0.01 | - | - | -0.20 | |
Quick Ratio | 7.08 | 11.90 | 6.96 | 26.97 | 0.18 | 0.05 | |
Current Ratio | 7.66 | 13.80 | 7.21 | 28.78 | 1.99 | 0.63 | |
Return on Equity (ROE) | -29.36% | -37.08% | -76.43% | -22.25% | -245.97% | -1146.60% | |
Return on Assets (ROA) | -33.14% | -34.72% | -38.82% | -15.04% | -40.80% | -25.96% | |
Return on Capital (ROIC) | -40.81% | -52.83% | -56.97% | -20.34% | -125.84% | -299.61% | |
Earnings Yield | -32.94% | -49.17% | -64.82% | -6.15% | -13.91% | -8.11% | |
FCF Yield | -97.92% | -150.08% | -75.44% | -18.71% | -7.88% | -3.22% | |
Buyback Yield / Dilution | -34.03% | -33.91% | -35.25% | -47.77% | -24.34% | -1.79% | |
Total Shareholder Return | -34.03% | -33.91% | -35.25% | -47.77% | -24.34% | -1.79% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.